For Big Pharma multinationals like Novartis, patent and data monopolies are the geese that lay golden eggs. So what do the EU-India free trade agreement negotiations, the Trans-Pacific Partnership Agreement negotiations, and the Novartis court case against India all have in common? They are three fronts on a Pharma-commanded war against strict limitations on patent and data monopolies in (...)
Novartis has been suing India for years challenging sec. 3(d) of India’s 2005 Amended Patents Act that erects high barriers to patenting minor modifications to existing medicines that provide no significant therapeutic benefit to patients. Although Novartis badly lost its first, broadest challenge to the Indian Amended Patents Act in 2007 (where its claimed that sec. 3(d) violated the WTO (...)
RSS 2.0